Suzetrigine in moderate to severe acute pain: a profile of its use
Abstract
Suzetrigine (JOURNAVX™), a first-in-class voltage-gated sodium channel 1.8 (NaV1.8) inhibitor, is an efficacious and well-tolerated non-opioid analgesic approved in the USA for the treatment of moderate to severe acute pain in adults. By selectively inhibiting the peripherally restricted NaV1.8 to reduce pain signal transmission, suzetrigine is expected to have minimal addictive potential. As shown in two double-blind, placebo- and active-controlled phase 3 trials in adults experiencing moderate to severe acute pain following a bunionectomy or abdominoplasty, a 48-h course of oral suzetrigine reduces pain intensity significantly more than placebo, although the trials did not demonstrate the superiority of suzetrigine over the opioid-based active comparator, hydrocodone bitartrate/acetaminophen 5 mg/325 mg. Suzetrigine is generally well tolerated; in clinical trials, nausea, constipation, and headache were the most common adverse events and most were of mild or moderate severity. No evidence of addictive potential for suzetrigine was found based on in vitro, preclinical, and clinical trial data. Pain is an unpleasant and emotional experience resulting from actual or potential tissue damage that is described as acute when it is sudden onset and lasts for ≤ 30 days. Sequelae from inadequately treated moderate to severe acute pain can be a substantial burden on patients, their families, healthcare systems, and society. Current treatment options for moderate to severe acute pain…
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.